Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) EBT Margin (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed EBT Margin for 16 consecutive years, with 66.42% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 5420.0% to 66.42% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 64.16% through Dec 2025, down 5263.0% year-over-year, with the annual reading at 64.16% for FY2025, 5263.0% down from the prior year.
  • EBT Margin hit 66.42% in Q4 2025 for Vanda Pharmaceuticals, down from 50.46% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 18.56% in Q2 2021 to a low of 74.67% in Q1 2025.
  • Historically, EBT Margin has averaged 10.69% across 5 years, with a median of 1.99% in 2023.
  • Biggest five-year swings in EBT Margin: surged 2141bps in 2023 and later crashed -6485bps in 2025.
  • Year by year, EBT Margin stood at 12.66% in 2021, then rose by 18bps to 14.91% in 2022, then tumbled by -125bps to 3.67% in 2023, then crashed by -233bps to 12.22% in 2024, then plummeted by -444bps to 66.42% in 2025.
  • Business Quant data shows EBT Margin for VNDA at 66.42% in Q4 2025, 50.46% in Q3 2025, and 66.34% in Q2 2025.